Literature DB >> 18335655

Treatment approaches for advanced cutaneous melanoma.

Jennifer A Stein1, Isaac Brownell.   

Abstract

Advanced melanoma has a poor prognosis, and standard adjuvant treatment offers little survival advantage. Current efforts are aimed at combining chemotherapy and novel immunomodulators, which these include melanoma vaccines, cytokines and anti-CTLA4 antibodies. Hundreds of combination therapies are currently in trials. All advanced melanoma patients should be considered for enrollment in a trial for their own benefit as well as for the advancement of melanoma treatment. Thus far, no single investigative approach stands out as highly effective, however, they all hold promise with rare patients showing durable responses. Most treatment protocols are evaluating combinations of adjuvant therapies, hoping to achieve a synergistic effect. Ongoing research into the biology of melanoma continues to suggest new drug targets that will block tumor progression or enhance host response. Until the day that an effective treatment for advanced melanoma is found, prevention and early detection will remain paramount in combating this deadly malignancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335655

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  5 in total

1.  Socioeconomic status and chemotherapy use for melanoma in older people.

Authors:  Carlos A Reyes-Ortiz; James S Goodwin; Dong D Zhang; Jean L Freeman
Journal:  Can J Aging       Date:  2011-03-01

2.  Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.

Authors:  Sandeep Singh; Rebecca Davis; Vignesh Alamanda; Roberta Pireddu; Daniel Pernazza; Said Sebti; Nicholas Lawrence; Srikumar Chellappan
Journal:  Mol Cancer Ther       Date:  2010-12-07       Impact factor: 6.261

3.  Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy.

Authors:  Frédéric Schmitt; Padavattan Govindaswamy; Olivier Zava; Georg Süss-Fink; Lucienne Juillerat-Jeanneret; Bruno Therrien
Journal:  J Biol Inorg Chem       Date:  2008-09-23       Impact factor: 3.358

4.  Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment.

Authors:  Rina A Anvekar; James J Asciolla; Derek J Missert; Jerry E Chipuk
Journal:  Front Oncol       Date:  2011-10-13       Impact factor: 6.244

5.  RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway.

Authors:  Angela M Keuling; Kathleen E A Felton; Arabesque A M Parker; Majid Akbari; Susan E Andrew; Victor A Tron
Journal:  PLoS One       Date:  2009-08-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.